Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析

◆英語タイトル:Relmada Therapeutics Inc (RLMDD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH212767FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treatment of neuropathic pain; REL-1028 BuTab, an oral tablet form of buprenorphine; REL-1015 LevoCap ER, an abuse resistant form of broad spectrum opioid levorphanol; and REL-1021 MepiGel, a topical gel dosage form of local anesthetic mepivacaine. It also develops analgesics medicines. The company offers products in the areas of chronic pain due to cancer, depression, ophthalmology, mitochondrial diseases, Rett syndrome and peripheral neuropathy. Relmada Therapeutics is headquartered in New York, the US.

Relmada Therapeutics Inc Key Recent Developments

Mar 23,2021: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Mar 18,2021: Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021
Mar 11,2021: Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
Jul 13,2020: Relmada Therapeutics announces uplisting to the Nasdaq Global Select Market
May 26,2020: Relmada Therapeutics appoints Molly Harper as Executive Vice President of operations

This comprehensive SWOT profile of Relmada Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Relmada Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Relmada Therapeutics Inc – Key Information
Relmada Therapeutics Inc – Overview
Relmada Therapeutics Inc – Key Employees
Relmada Therapeutics Inc – Key Employee Biographies
Relmada Therapeutics Inc – Key Operational Heads
Relmada Therapeutics Inc – Major Products and Services
Relmada Therapeutics Inc – History
Relmada Therapeutics Inc – Company Statement
Relmada Therapeutics Inc – Locations And Subsidiaries
Relmada Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Relmada Therapeutics Inc – Business Description
Relmada Therapeutics Inc – Corporate Strategy
Relmada Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Relmada Therapeutics Inc – Strengths
Relmada Therapeutics Inc – Weaknesses
Relmada Therapeutics Inc – Opportunities
Relmada Therapeutics Inc – Threats
Relmada Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Relmada Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Relmada Therapeutics Inc, Key Information
Relmada Therapeutics Inc, Key Ratios
Relmada Therapeutics Inc, Share Data
Relmada Therapeutics Inc, Major Products and Services
Relmada Therapeutics Inc, History
Relmada Therapeutics Inc, Key Employees
Relmada Therapeutics Inc, Key Employee Biographies
Relmada Therapeutics Inc, Key Operational Heads
Relmada Therapeutics Inc, Other Locations
Relmada Therapeutics Inc, Subsidiaries
Relmada Therapeutics Inc, Key Competitors
Relmada Therapeutics Inc, SWOT Analysis
Relmada Therapeutics Inc, Ratios based on current share price
Relmada Therapeutics Inc, Annual Ratios
Relmada Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Florida Public Utilities Co:企業の戦略的SWOT分析
    Florida Public Utilities Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • HeartWare International Inc:企業の戦略的SWOT分析
    HeartWare International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Molecular Health GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Health GmbH (Molecular Health) is a biomedical company that designs, develops, manufactures and commercializes software systems which performs integrated analysis of clinical and genomic patient data to support treatment decisions and provide related services. The company offers Mo …
  • Bullfrog Power Inc.:電力:M&Aディール及び事業提携情報
    Summary Bullfrog Power Inc. (Bullfrog Power) is a provider of green energy. It offers renewable energy solutions that help businesses and houses in reducing their environmental impact. Bullfrog's product portfolio includes green electricity, green fuel and green natural gas. The company, through its …
  • Beactica AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Beactica AB (Beactica) is a drug discovery company develops a pipeline of novel and mechanistically defined small molecule therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate ana …
  • Diazyme Laboratories Inc:製品パイプライン分析
    Summary Diazyme Laboratories Inc (Diazyme Laboratories) is a developer of diagnostic reagents. The company’s products include vitamin D assays, vitamin D assay for clinical chemistry analyzers, adenosine deaminase assay, cardiac troponin I assay, creatinine assay, D-dimer assay, direct enzymatic HbA …
  • L’Occitane International SA:企業の戦略・SWOT・財務分析
    L'Occitane International SA - Strategy, SWOT and Corporate Finance Report Summary L'Occitane International SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • The Independent Order of Foresters:企業の戦略的SWOT分析
    The Independent Order of Foresters - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Vifor Pharma AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Vifor Pharma AG (Vifor Pharma) a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for tre …
  • Euronav NV (EURN):企業の財務・戦略的SWOT分析
    Summary Euronav NV (Euronav) is a transportation and logistics company that offers shipping services. The company provides sea-borne transportation, tanker shipping, proactive management, fleet composition and ship management services, among others. It offers ship management services which includes …
  • Fintel Energia Group SpA (FTL):企業の財務・戦略的SWOT分析
    Summary Fintel Energia Group SpA (Fintel) is a utility service provider that supplies electricity and natural gas. The company's services include designing, consultation, and installation of technologies and system of production of renewable energies for the Group and to third parties. It also provi …
  • Guthy-Renker LLC:企業の戦略的SWOT分析
    Guthy-Renker LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Qatar Fuel (WOQOD) (QFLS):企業の財務・戦略的SWOT分析
    Qatar Fuel (WOQOD) (QFLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Probi AB (PROB):企業の財務・戦略的SWOT分析
    Probi AB (PROB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • LPP SA (LPP):企業の財務・戦略的SWOT分析
    LPP SA (LPP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Columbia Sportswear Co (COLM):企業の財務・戦略的SWOT分析
    Columbia Sportswear Co (COLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Sandoz International GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Sandoz International GmbH (Sandoz), a subsidiary of Novartis AG develops, manufactures and commercializes generic pharmaceutical products. The company provides biosimilars, generic antibiotics, dermatology and transplantation medicines. Its biosimilars comprise Omnitrope, Binocrit and Zarzio …
  • Parion Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Parion Sciences Inc (Parion Sciences) is a development stage company that provides research, development and commercialization of treatments to improve patient’s innate mucosal surface defenses. The company’s pipeline products include P-1037, a clinical stage ENaC blocker for pulmonary disea …
  • E*Trade Financial Corp:企業の戦略・SWOT・財務情報
    E*Trade Financial Corp - Strategy, SWOT and Corporate Finance Report Summary E*Trade Financial Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Aabar Investments:企業の戦略的SWOT分析
    Aabar Investments - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆